Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Asan Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized double-blinded study to investigate in which the groups are designated as the control group and the restrictive group to further evaluate significant differences in intraoperative blood loos during burn surgery.
This is a randomized double-blinded study to investigate the effect of fluid restriction and vasopressin on blood loss during surgery of the burn patients. The groups are designated as the control group and the restrictive group to further evaluate significant differences in intraoperative blood loss during the surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | No Intervention | Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution. | |
| Restrictive group | Experimental | Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia. Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vasopressin | Drug | Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure. |
| Measure | Description | Time Frame |
|---|---|---|
| Intraoperative blood loss | Comparison of the amounts of estimated blood loss in the two groups. | At the end of the surgery, approximately 3 hrs |
| Measure | Description | Time Frame |
|---|---|---|
| Intraoperative red blood cell transfusion | Comparison of total units of red blood cell transfusion in the two groups. | At the end of the surgery, approximately 3 hrs |
| Postoperative pulmonary complication |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hee Yeong Kim, MD | Contact | 82226395650 | kimhy@hallym.or.kr |
| Name | Affiliation | Role |
|---|---|---|
| Young-Kug Kim, MD, PhD | Asan Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hangang Sacred Heart Hospital | Recruiting | Seoul | 07247 | South Korea |
Not provided
| ID | Term |
|---|---|
| D014667 | Vasopressins |
| D001127 | Arginine Vasopressin |
| ID | Term |
|---|---|
| D010909 | Pituitary Hormones, Posterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
Comparison of postoperative pulmonary complication in the two groups.
| Within 7 postoperative days |
| Postoperative cardiovascular complication | Comparison of postoperative cardiovascular complication in the two groups. | Within 7 postoperative days |
| Postoperative renal complication | Comparison of postoperative acute kidney injury in the two groups. | Within 7 postoperative days |
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |